AKT1 and acute lymphoblastic leukemia: The enhanced autophagic response suggests that dual inhibition amplifies cytotoxicity and highlights the therapeutic potential of concurrently targeting Gli1 and Akt in T-ALL [10] and represents a promising strategy to overcome intrinsic resistance mechanisms with robust anti-leukemic effects [47].